These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33732990)

  • 21. More dissimilarities than affinities between DNAJB11-PKD and ADPKD.
    Pisani I; Allinovi M; Palazzo V; Zanelli P; Gentile M; Farina MT; Giuliotti S; Cravedi P; Delsante M; Maggiore U; Fiaccadori E; Manenti L
    Clin Kidney J; 2022 Jun; 15(6):1179-1187. PubMed ID: 35664268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease.
    Segarra-Medrano A; Martin M; Agraz I; Vilaprinyó M; Chamoun B; Jatem E; Molina M; Colàs-Campàs L; Garcia-Carrasco A; Roche S
    Clin Kidney J; 2020 Aug; 13(4):607-612. PubMed ID: 32905289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Research progress in autosomal dominant polycystic kidney disease].
    Hu S; Li D; Tan X; Gu J; Chen M; Zhang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 44(10):1179-1187. PubMed ID: 31857514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary biomarkers at early ADPKD disease stage.
    Petzold K; Poster D; Krauer F; Spanaus K; Andreisek G; Nguyen-Kim TD; Pavik I; Ho TA; Serra AL; Rotar L
    PLoS One; 2015; 10(4):e0123555. PubMed ID: 25875363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
    Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
    Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.
    Irazabal MV; Blais JD; Perrone RD; Gansevoort RT; Chapman AB; Devuyst O; Higashihara E; Harris PC; Zhou W; Ouyang J; Czerwiec FS; Torres VE
    Kidney Int Rep; 2016 Nov; 1(4):213-220. PubMed ID: 29142926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease.
    Jones BE; Mkhaimer YG; Rangel LJ; Chedid M; Schulte PJ; Mohamed AK; Neal RM; Zubidat D; Randhawa AK; Hanna C; Gregory AV; Kline TL; Zoghby ZM; Senum SR; Harris PC; Torres VE; Chebib FT
    Kidney360; 2022 Mar; 3(3):465-476. PubMed ID: 35582184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease.
    Blijdorp CJ; Severs D; Musterd-Bhaggoe UM; Gansevoort RT; Zietse R; Hoorn EJ;
    Nephrol Dial Transplant; 2021 Dec; 36(12):2248-2255. PubMed ID: 33377160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. End-Stage Kidney Disease in Patients With Autosomal Dominant Polycystic Kidney Disease: A 12-Year Study Based on the Canadian Organ Replacement Registry.
    Budhram B; Akbari A; Brown P; Biyani M; Knoll G; Zimmerman D; Edwards C; McCormick B; Bugeja A; Sood MM
    Can J Kidney Health Dis; 2018; 5():2054358118778568. PubMed ID: 29977583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
    Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased Body Fat and Organic Acid Anions Production Are Associated with Larger Kidney Size in ADPKD.
    Dos Santos Dutra A; Rodrigues FG; da Rocha DR; Vendramini LC; de Matos ACC; Heilberg IP
    Medicina (Kaunas); 2022 Jan; 58(2):. PubMed ID: 35208476
    [No Abstract]   [Full Text] [Related]  

  • 33. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China.
    Xue C; Zhou CC; Wu M; Mei CL
    Kidney Dis (Basel); 2016 Oct; 2(3):111-119. PubMed ID: 27921038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL; Cadnapaphornchai MA; Chonchol MB; Schrier RW; Gitomer B
    Am J Nephrol; 2016; 44(3):171-8. PubMed ID: 27548646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease.
    Bae KT; Shi T; Tao C; Yu ASL; Torres VE; Perrone RD; Chapman AB; Brosnahan G; Steinman TI; Braun WE; Srivastava A; Irazabal MV; Abebe KZ; Harris PC; Landsittel DP;
    J Am Soc Nephrol; 2020 Jul; 31(7):1640-1651. PubMed ID: 32487558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease.
    O'Sullivan DA; Torres VE; Gabow PA; Thibodeau SN; King BF; Bergstralh EJ
    Am J Kidney Dis; 1998 Dec; 32(6):976-83. PubMed ID: 9856513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients.
    Girardat-Rotar L; Braun J; Puhan MA; Abraham AG; Serra AL
    BMC Nephrol; 2017 Jul; 18(1):241. PubMed ID: 28716055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD.
    Perrone RD; Oberdhan D; Ouyang J; Bichet DG; Budde K; Chapman AB; Gitomer BY; Horie S; Ong ACM; Torres VE; Turner AN; Krasa H
    Kidney Int Rep; 2023 May; 8(5):989-1001. PubMed ID: 37180499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
    Kim K; Trott JF; Gao G; Chapman A; Weiss RH
    BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.